The Rinpharm company has been granted a registration certificate by the Ministry of Health of the Russian Federation for their groundbreaking drug Talopsa (Sultiam). This medication has been specifically developed to effectively halt epilepsy attacks and address behavioral abnormalities in patients experiencing exacerbations of the disease.
The drug is provided in tablet form with dosages of both 50 and 200 mg. It is suitable for prescription to individuals of all ages, including children as young as three years old. The instructions list several side effects, including an elevated risk of suicidal behavior, harmful effects on the liver, acute renal failure, loss of appetite, difficulty breathing, upset stomach.
Talopsa underwent pre-approval trials to determine its bioequivalence with the original Ospolot drug, which contains the same active ingredient and is manufactured by the well-known German company Desitin Arzneimittel GmbH. Sultiam belongs to the group of second-generation anticonvulsants (carbonic anhydrase inhibitor, a derivative of cyclic sulfonamide).
